Total protein was extracted from the YYFZBJS-treated CRC cells or mouse CRC tissues using RIPA lysis buffer supplemented with a phosphatase and protease inhibitor cocktail. Protein concentration was then measured using a BCA assay kit according to manufacturer instructions. Next, 40μg of each sampled were resolved using 10% SDS-PAGE and transferred onto 0.45μm PVDF membranes (Millipore, USA). Membranes were then blocked using 5% skimmed milk in TBST for 1 h at room temperature, and then washed with TBST. The membranes were then incubated overnight (at 4°C) with antibodies against CDK1(1:1,000; Abcam), p-PI3K (1:1,000; CST), PI3K (1:1,000; CST), p-AKT (1:1,000; CST), AKT (1:1,000; CST) and β-actin (1:2000, ABclonal). The membranes were then washed and incubated with HRP-conjugated goat anti-mouse or anti-rabbit (1:1000) secondary antibodies for 2 h, at room temperature. Signal was then developed using an ECL kit.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.